Deal closure is a procedural step with no new financial or strategic information. Monitor BioMarin's next earnings call for integration updates and any pipeline contributions from Alesta. No immediate trading catalyst.
BMRN drugs
BMRN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 1 $64.84entry
- T+1 · 3mo ago +3.29%α +2.84% · $66.97
- T+5 · 2mo ago −0.66%α −0.74% · $64.41
- T+20 · 7w ago −7.46%α −7.78% · $60.00
- T+53 · todayOpen
- T+60 · in 8d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioMarin completed its previously announced acquisition of Alesta Therapeutics B.V. on August 31, 2026, making Alesta a wholly owned subsidiary. The filing confirms deal closure but provides no financial terms, pipeline details, or strategic rationale, making it a routine administrative update with limited standalone trading impact.
Key Facts
- BioMarin completed the acquisition of Alesta Therapeutics B.V. on August 31, 2026.
- Alesta is now a wholly owned subsidiary of BioMarin.
- The acquisition was previously announced in an 8-K filed on August 18, 2026.
- No financial terms, deal value, or strategic details are disclosed in this filing.
Financial Impact
No financial terms disclosed in this filing.
Risk Factors
- Integration risk from the Alesta acquisition is unquantified.
- No disclosure of deal value or expected financial impact limits assessment of dilution or ROI.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-377696 |
| Document: 0001193125-26-377696-index-headers.html | 0001193125-26-377696 |
| Document: 0001193125-26-377696-index.html | 0001193125-26-377696 |
| Document: 0001193125-26-377696.txt | 0001193125-26-377696 |
Track record
16 reports on BMRN
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +8.91% at T+60 after the Apr 27, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
- Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
- Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Viewing Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Sep 1, 202610w ago Press Release Neutral 4/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers